A Form 4 filed on September 10, 2026, disclosed that David R. Pelizzon, a director and 10% owner of OrthoPediatrics Corp, reported the sale of 302,369 shares of common stock on behalf of Squadron Capital LLC at a weighted average price of $21.01 per share.
Key Highlights
- Reporting person: David R. Pelizzon, listed as a Director and 10% Owner of OrthoPediatrics Corp (NASDAQ:KIDS).
- Shares sold: 302,369 shares of common stock disposed of (Transaction Code S) on September 10, 2026.
- Weighted average price: $21.01 per share; individual transactions ranged from $21.00 to $21.69, inclusive, according to the filing.
- Stated purpose: The filing states the sale "was undertaken by Squadron Capital LLC to provide additional capital for its other portfolio businesses."
- Post-transaction indirect holdings: 6,201,764 shares held indirectly through Squadron Capital LLC following the reported transaction.
- Direct holdings: 44,384 shares held directly, which the filing notes includes restricted stock awards totaling 17,959 shares.
- Beneficial ownership disclaimer: Pelizzon expressly disclaims beneficial ownership of the Squadron-held shares except to the extent of his pecuniary interest.
Squadron Capital LLC Sells OrthoPediatrics Shares in Multiple Transactions
According to the Form 4 filed with the SEC, David R. Pelizzon, serving as President and a member of the Managing Committee of Squadron Capital LLC, reported the disposal of 302,369 shares of OrthoPediatrics Corp common stock. The transaction, coded "S" for a sale, took place on September 10, 2026. The filing identifies Pelizzon as both a Director and a 10% Owner of the issuer.
The filing notes that the $21.01 price is a weighted average, with the actual sales occurring across multiple transactions at prices ranging from $21.00 to $21.69, inclusive. Pelizzon, per the filing, "undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."
Following the reported transactions, the filing shows 6,201,764 shares beneficially owned indirectly through Squadron Capital LLC, and 44,384 shares held directly by Pelizzon, the latter of which includes restricted stock awards totaling 17,959 shares. The filing was signed by Daniel J. Gerritzen as Attorney-in-Fact on September 10, 2026.
What Was Disclosed
The filing reported a sale of 302,369 shares of OrthoPediatrics Corp common stock by Squadron Capital LLC, attributed to Pelizzon as a director and 10% owner, at a weighted average price of $21.01, with post-transaction beneficial ownership of 6,201,764 shares held indirectly.


Please wait processing your request...